Eiger BioPharmaceuticals, Inc.
EIGRQ · OTC
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.01 | -0.00 | 0.09 | 0.21 |
| FCF Yield | -718.53% | -169.68% | -68.26% | -18.34% |
| EV / EBITDA | -0.37 | -0.69 | -2.45 | -5.68 |
| Quality | ||||
| ROIC | -268.22% | -96.99% | -73.36% | -48.63% |
| Gross Margin | 95.09% | 80.13% | 87.28% | 0.00% |
| Cash Conversion Ratio | 0.99 | 0.86 | 2.11 | 0.97 |
| Growth | ||||
| Revenue 3-Year CAGR | 9.11% | – | – | – |
| Free Cash Flow Growth | 10.28% | 30.69% | -89.54% | 1.01% |
| Safety | ||||
| Net Debt / EBITDA | -0.22 | -0.16 | -0.14 | -0.06 |
| Interest Coverage | -13.13 | -22.44 | -21.62 | -17.29 |
| Efficiency | ||||
| Inventory Turnover | 0.50 | 0.94 | 0.59 | 6.94 |
| Cash Conversion Cycle | -224.69 | -786.75 | -1,140.73 | -2,573.11 |